Willis Towers Watson Valuation
Is 0Y4Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0Y4Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0Y4Q ($309.91) is trading above our estimate of fair value ($188.87)
Significantly Below Fair Value: 0Y4Q is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0Y4Q?
Key metric: As 0Y4Q is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0Y4Q's PS Ratio? | |
|---|---|
| PS Ratio | 3.2x |
| Sales | US$9.81b |
| Market Cap | US$30.98b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.6x |
| Enterprise Value/EBITDA | 13.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0Y4Q's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
LGEN Legal & General Group | 1x | 6.9% | UK£12.7b |
AV. Aviva | 0.6x | 9.0% | UK£12.9b |
PRU Prudential | 1.9x | 21.0% | UK£16.6b |
PHNX Phoenix Group Holdings | 0.2x | -27.6% | UK£5.0b |
0Y4Q Willis Towers Watson | 3.2x | 1.0% | US$31.0b |
Price-To-Sales vs Peers: 0Y4Q is expensive based on its Price-To-Sales Ratio (3.2x) compared to the peer average (0.9x).
Price to Sales Ratio vs Industry
How does 0Y4Q's PS Ratio compare vs other companies in the GB Insurance Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
RQIH R&Q Insurance Holdings | 0.001x | n/a | US$360.20k |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 0Y4Q is expensive based on its Price-To-Sales Ratio (3.2x) compared to the European Insurance industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 0Y4Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.2x |
| Fair PS Ratio | 1.5x |
Price-To-Sales vs Fair Ratio: 0Y4Q is expensive based on its Price-To-Sales Ratio (3.2x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$309.91 | US$331.84 +7.1% | 9.0% | US$369.00 | US$262.00 | n/a | 19 |
| Nov ’25 | US$300.90 | US$324.79 +7.9% | 8.0% | US$369.00 | US$262.00 | n/a | 19 |
| Oct ’25 | US$302.59 | US$308.96 +2.1% | 7.6% | US$365.00 | US$253.00 | n/a | 19 |
| Sep ’25 | US$291.60 | US$309.07 +6.0% | 6.3% | US$335.00 | US$253.00 | n/a | 19 |
| Aug ’25 | US$283.84 | US$308.59 +8.7% | 6.4% | US$335.00 | US$253.00 | n/a | 19 |
| Jul ’25 | US$260.65 | US$299.17 +14.8% | 6.2% | US$329.00 | US$253.00 | n/a | 19 |
| Jun ’25 | US$254.09 | US$298.72 +17.6% | 6.2% | US$329.00 | US$253.00 | n/a | 19 |
| May ’25 | US$254.69 | US$297.35 +16.8% | 6.6% | US$329.00 | US$253.00 | n/a | 19 |
| Apr ’25 | US$275.70 | US$292.09 +5.9% | 9.2% | US$329.00 | US$236.00 | n/a | 19 |
| Mar ’25 | US$270.60 | US$290.35 +7.3% | 8.8% | US$320.00 | US$236.00 | n/a | 19 |
| Feb ’25 | US$247.35 | US$259.89 +5.1% | 10.1% | US$316.00 | US$215.00 | n/a | 18 |
| Jan ’25 | US$240.74 | US$248.65 +3.3% | 8.0% | US$284.00 | US$210.00 | n/a | 17 |
| Dec ’24 | US$246.46 | US$248.65 +0.9% | 8.0% | US$284.00 | US$210.00 | n/a | 17 |
| Nov ’24 | US$234.89 | US$248.65 +5.9% | 8.0% | US$284.00 | US$210.00 | US$300.90 | 17 |
| Oct ’24 | US$212.43 | US$238.94 +12.5% | 7.2% | US$265.00 | US$205.00 | US$302.59 | 17 |
| Sep ’24 | US$206.44 | US$239.24 +15.9% | 7.5% | US$270.00 | US$205.00 | US$291.60 | 17 |
| Aug ’24 | US$212.43 | US$244.53 +15.1% | 7.5% | US$285.00 | US$218.00 | US$283.84 | 17 |
| Jul ’24 | US$235.33 | US$257.82 +9.6% | 6.9% | US$285.00 | US$230.00 | US$260.65 | 17 |
| Jun ’24 | US$220.28 | US$258.25 +17.2% | 7.1% | US$285.00 | US$230.00 | US$254.09 | 16 |
| May ’24 | US$225.28 | US$262.18 +16.4% | 7.5% | US$302.00 | US$230.00 | US$254.69 | 17 |
| Apr ’24 | US$231.23 | US$266.41 +15.2% | 7.7% | US$303.00 | US$231.00 | US$275.70 | 17 |
| Mar ’24 | US$233.16 | US$265.65 +13.9% | 8.1% | US$303.00 | US$231.00 | US$270.60 | 17 |
| Feb ’24 | US$251.44 | US$259.88 +3.4% | 8.8% | US$303.00 | US$228.00 | US$247.35 | 17 |
| Jan ’24 | US$245.08 | US$242.25 -1.2% | 10.3% | US$302.00 | US$210.00 | US$240.74 | 16 |
| Dec ’23 | US$247.12 | US$238.75 -3.4% | 8.5% | US$288.00 | US$210.00 | US$246.46 | 16 |
| Nov ’23 | US$221.77 | US$237.94 +7.3% | 7.9% | US$288.00 | US$210.00 | US$234.89 | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
FBD Holdings
€523.9m
Through its subsidiaries, engages in the underwriting of general insurance to farmers, private individuals, and business owners in Ireland.
FBH
€13.15
7D
0%
1Y
1.5%
Swiss Re
CHF 28.1b
Provides wholesale reinsurance, insurance, other insurance-based forms of risk transfer, and other insurance-related services worldwide.
SRENZ
CHF 96.62
7D
2.0%
1Y
4.1%
Old Mutual
R55.8b
Provides financial services primarily in South Africa and rest of Africa.
OMUL
R0.56
7D
2.1%
1Y
6.5%